compounded semaglutide deadline As of February 21, 2025, the FDA updated its drug shortage list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A There's lots going on this

Clinical Benefits of Microdosing: Reduced Side Effects: Lower starting doses minimize nausea, vomiting, and other gastrointestinal symptoms that can lead to treatment discontinuation Individualized Titration: Ability to make small incremental adjustments based on patient response and tolerance Cost Effectiveness: Extended use of each medication vial, making treatment more accessible Improved Adherence: Better tolerability leads to sustained treatment compliance Dosing Protocols for Microdosing: Research supports starting with doses as low as 0.15 mg per week for compounded semaglutide, with gradual titration based on individual response.[5] The flexible dosing allows providers to find the optimal therapeutic dose for each patient while maintaining safety and efficacy

For context on the broader landscape, understanding how mazdutide compares to tirzepatide and how cagrilintide fits in shows just how active the GLP-1 research space has become

The implications of this when using incretins for weight loss are somewhat different compared to use for managing hormones in type 1 diabetes

About 63% achieved at least 5% weight loss, and 33% lost 10% or more

Patients should seek immediate medical attention for severe abdominal pain

Speak to one of our clinicians to talk through whether a switch makes sense for you